- Home
- PTPI vs SNPX Comparison
PTPI vs SNPX Comparison
Compare PTPI & SNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTPI
- SNPX
- Stock Information
- Founded
- PTPI 2020
- SNPX 2012
- Country
- PTPI United States
- SNPX United States
- Employees
- PTPI N/A
- SNPX N/A
- Industry
- PTPI Biotechnology: Pharmaceutical Preparations
- SNPX Medicinal Chemicals and Botanical Products
- Sector
- PTPI Health Care
- SNPX Health Care
- Exchange
- PTPI Nasdaq
- SNPX Nasdaq
- Market Cap
- PTPI 2.6M
- SNPX 3.1M
- IPO Year
- PTPI N/A
- SNPX N/A
- Fundamental
- Price
- PTPI $0.04
- SNPX $2.12
- Analyst Decision
- PTPI
- SNPX Strong Buy
- Analyst Count
- PTPI 0
- SNPX 1
- Target Price
- PTPI N/A
- SNPX $14.00
- AVG Volume (30 Days)
- PTPI 91.2M
- SNPX 11.9K
- Earning Date
- PTPI 05-14-2025
- SNPX 05-14-2025
- Dividend Yield
- PTPI N/A
- SNPX N/A
- EPS Growth
- PTPI N/A
- SNPX N/A
- EPS
- PTPI N/A
- SNPX N/A
- Revenue
- PTPI $5,112,043.00
- SNPX N/A
- Revenue This Year
- PTPI $9.25
- SNPX N/A
- Revenue Next Year
- PTPI N/A
- SNPX N/A
- P/E Ratio
- PTPI N/A
- SNPX N/A
- Revenue Growth
- PTPI N/A
- SNPX N/A
- 52 Week Low
- PTPI $0.04
- SNPX $1.84
- 52 Week High
- PTPI $0.90
- SNPX $5.38
- Technical
- Relative Strength Index (RSI)
- PTPI 34.54
- SNPX 37.61
- Support Level
- PTPI $0.06
- SNPX $1.93
- Resistance Level
- PTPI $0.11
- SNPX $2.29
- Average True Range (ATR)
- PTPI 0.01
- SNPX 0.18
- MACD
- PTPI 0.00
- SNPX 0.01
- Stochastic Oscillator
- PTPI 1.45
- SNPX 39.63
About PTPI Petros Pharmaceuticals Inc.
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on therapeutics that promote medication adherence, tolerability, and preservation of male organic function. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Medical Devices segment. The Prescription Medications segment consists of operations related to vacuum erection devices, which are sold domestically and internationally.
About SNPX Synaptogenix Inc.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.